The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease
Abstract
Summary: Objectives To explore associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease (NAFLD). Design and patients In a cross‐sectional study, we enrolled 60 consecutive NAFLD patients and 60 age‐, sex‐ and body mass index (BMI)‐matched healthy controls. Measurements NAFLD (by liver biopsy), plasma adiponectin concentrations, insulin resistance (by homeostasis model assessment, HOMA‐IR) and metabolic syndrome (MetS) features. Results NAFLD patients had a marked decrease in plasma adiponectin concentration (6·1 ± 2·8 vs. 13·6 ± 3·8 µg/ml, P < 0·001) compared with matched controls. MetS, as defined by the Adult Treatment Panel III (ATP III) criteria, and its individual components were more frequent among NAFLD patients. The marked differences in adiponectin concentrations that were observed between the groups were little affected by adjustment for age, sex, BMI, HOMA‐IR score and MetS components. Notably, decreased adiponectin levels were closely associated with the degree of hepatic steatosis, necroinflammation and fibrosis (P < 0·001 for all) among NAFLD patients. By logistic regression analysis, low adiponectin levels independently predicted hepatic steatosis [odds ratio (OR) 2·3, 95% confidence interval (CI) 1·5–5·8, P < 0·001] and necroinflammation (OR 3·1, 95% CI 1·9–7, P < 0·001), but not fibrosis (P = 0·07), after adjustment for age, sex, BMI, HOMA‐IR and MetS components. Conclusions NAFLD patients have markedly lower plasma adiponectin concentrations than control subjects. Low adiponectin levels are strongly associated with the severity of liver histology, thus further supporting the hypothesis that adiponectin might be involved in the development of NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Bonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456
Self-citationXu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Beyond insulin resistance in NASH: TNF-α or adiponectin?
Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G., Kriketos, A., & George, J. (2004) · Hepatology · doi:10.1002/hep.20280 · Cited by 942
Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2169 · Cited by 524
Cited by
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Self-citationAdams, L. A., Anstee, Q. M., Tilg, H., & Targher, G. (2017) · Gut · doi:10.1136/gutjnl-2017-313884 · Cited by 1,174
Self-citationNon-alcoholic fatty liver disease and increased risk of cardiovascular disease
Targher, G., & Arcaro, G. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.021 · Cited by 551
Self-citationViollet, B., Guigas, B., Leclerc, J., Hébrard, S., Lantier, L., Mounier, R., Andreelli, F., & Foretz, M. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.01970.x · Cited by 486
Adipokines in liver diseases #
Marra, F., & Bertolani, C. (2009) · Hepatology · doi:10.1002/hep.23046 · Cited by 471
Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis
Anderson, N., & Borlak, J. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.00001 · Cited by 385
Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation
Peverill, W., Powell, L., & Skoien, R. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15058591 · Cited by 376
Diagnosis and Therapy of Nonalcoholic Steatohepatitis
Torres, D. M., & Harrison, S. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.077 · Cited by 354
Ix, J. H., & Sharma, K. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009080820 · Cited by 348
Nonalcoholic Fatty Liver Disease: A Review and Update
Lewis, J. R., & Mohanty, S. R. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-1081-0 · Cited by 345
Animal models of NASH: Getting both pathology and metabolic context right
Larter, C. Z., & Yeh, M. M. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05543.x · Cited by 337
Non-alcoholic fatty liver disease and the metabolic syndrome: An update
Rector, R. S., Thyfault, J. P., Wei, Y., & Ibdah, J. A. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.185 · Cited by 332
Hepatic lipid metabolism and non-alcoholic fatty liver disease
Tessari, P., Coracina, A., Cosma, A., & Tiengo, A. (2009) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.12.015 · Cited by 314
Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis
Polyzos, S. A., Toulis, K. A., Goulis, D. G., Zavos, C., & Kountouras, J. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.003 · Cited by 311
Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease
Targher, G., & Byrne, C. D. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.16 · Cited by 309
Self-citationNonalcoholic Fatty Liver Disease
Carr, R. M., Oranu, A., & Khungar, V. (2016) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.07.003 · Cited by 280
The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., Zavos, C., & Tsiaousi, E. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01176.x · Cited by 277
Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic Steatohepatitis
Cusi, K. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.009 · Cited by 266
Pathogenesis and management issues for non-alcoholic fatty liver disease
Duvnjak, M. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i34.4539 · Cited by 264
Nelson, A., Torres, D. M., Morgan, A. E., Fincke, C., & Harrison, S. A. (2009) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31819c392e · Cited by 230
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis
Gisondi, P., Targher, G., Zoppini, G., & Girolomoni, G. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.020 · Cited by 225
Self-citationHajifathalian, K., Torabi Sagvand, B., & McCullough, A. J. (2019) · Hepatology · doi:10.1002/hep.30226 · Cited by 128
“NAFLD is associated with insulin resistance and increased triglyceride levels,(39-41) decreased adiponectin levels,(42-45) and metabolic syndrome.”
Background(2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.07.012 · Cited by 46
Non-alcoholic fatty liver disease: pathogenesis and models
Zhong, H. (2024) · American Journal of Translational Research · doi:10.62347/kmsa5983 · Cited by 37
Metadata
- Authors
- Targher, G., Bertolini, L., Rodella, S., Zoppini, G., Scala, L., Zenari, L., & Falezza, G.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2006-04-12
- Volume
- 64
- Issue
- 6
- Pages
- 679-683
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2068634545
- Cited by
- 172
- References
- 6
- FWCI
- 11.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.